市場調査レポート

商品コード

1563121

細胞・遺伝子治療薬のバイオ製造の世界市場：製品タイプ・段階・用途・エンドユーザー・地域別の予測 (～2032年)

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type, By Usage, By Application, By End User And By Region - Forecast Till 2032

出版日: 2024年08月10日
発行: Market Research Future
ページ情報: 英文 131 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,950 727,600円

レポートPDF、Excelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Multi User License)

USD 5,950 874,590円

レポートPDF、Excelを同一企業内の最大15名がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Enterprise License)

USD 7,250 1,065,677円

レポートPDF、Excelを同一企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDF、Excelの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

細胞・遺伝子治療薬のバイオ製造の市場規模は2022年の126億米ドル、2023年の139億米ドルから、予測期間中は10.60%のCAGRで推移し、2032年には312億米ドルの規模に成長すると予測されています。市場成長を促進している主な要因は、細胞・遺伝子治療薬研究への投資の増加です。

細胞・遺伝子治療薬の市場は急速な成長を遂げており、製造ソリューションに対する需要の高まりが細胞・遺伝子治療薬のバイオ製造市場を牽引しています。有望な臨床試験結果や新規細胞・遺伝子治療薬の承認を受け、商業化の要件を満たすために製造量を増やす必要性が高まっています。市場の急激な成長により、効率的でスケーラブルで費用対効果の高いバイオ製造プロセスとインフラの開発が求められています。細胞・遺伝子治療薬製品の需要増加に対応して、バイオ製造企業は自動化、シングルユースシステム、クローズドシステム・バイオリアクターなどの先端技術に投資しています。

地域別展望

同市場は、さまざまな要因から北米が支配的立場に位置付けています。第一に、北米地域には細胞・遺伝子治療薬のR&Dに積極的に関与する製薬会社やバイオテクノロジー企業の盛んなエコシステムがあります。第二に、北米には確立された規制の枠組みや支援政策があり、市場の成長を促進しています。

欧州の細胞・遺伝子治療薬のバイオ製造市場は第2位の市場シェアを示し、これは有能な人材に起因しています。欧州が第2位のシェアを獲得した背景には、有能な人材、高度なインフラ、確立されたバイオ医薬品産業を有していることなど、いくつかの要因があります。

アジア太平洋市場は、2024年から2032年にかけてもっとも急速な成長を遂げると予測されています。同地域のバイオ医薬品産業は、特に細胞・遺伝子治療薬分野へのR&Dの増加により、加速度的な成長を遂げています。

当レポートでは、世界の細胞・遺伝子治療薬のバイオ製造の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

LIST OF TABLES

TABLE 1 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 11 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 12 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 13 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 15 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 16 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 17 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 19 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 20 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 21 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 22 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 23 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 24 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 25 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 26 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 27 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 28 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 29 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 30 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 31 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 32 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 33 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 34 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 35 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 36 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 37 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 38 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 39 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 40 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 41 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 42 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 43 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 44 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 45 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 46 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 47 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 48 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 49 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 50 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 51 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 52 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 53 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 54 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 55 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 56 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 57 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 58 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 59 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 60 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 61 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 62 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 63 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 64 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 65 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 66 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 67 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 68 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 69 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 70 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 73 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 74 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 75 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 76 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 77 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 78 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 79 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 80 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 81 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 82 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 83 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 84 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 85 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 86 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 87 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 88 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 89 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 90 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY PRODUCT TYPE,
FIGURE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY USAGE,
FIGURE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY APPLICATION,
FIGURE 7 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY END USER,
FIGURE 8 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 10 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 11 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 12 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
FIGURE 13 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 LONZA GROUP: SWOT ANALYSIS
FIGURE 16 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 18 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 MERCK KGAA: SWOT ANALYSIS
FIGURE 20 WUXI APPTEC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 WUXI APPTEC: SWOT ANALYSIS
FIGURE 22 CATALENT, INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 CATALENT, INC..: SWOT ANALYSIS
FIGURE 24 SAMSUNG BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 SAMSUNG BIOLOGICS: SWOT ANALYSIS
FIGURE 26 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: SWOT ANALYSIS
FIGURE 28 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 30 CYTIVA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 CYTIVA: SWOT ANALYSIS
FIGURE 32 NOVASEP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 NOVASEP: SWOT ANALYSIS

Product Code: MRFR/HC/20294-HCR

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

Market Overview

In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.

The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth as a result of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.

Market segment insights

Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.

Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.

Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.

The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.

Regional Perspectives

The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America because of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.

The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.

The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth as a result of the growing investment in research and development, particularly in the fields of cell and gene therapy.

Major Players

Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. DEFINITION
2.2. SCOPE OF THE STUDY
- 2.2.1. RESEARCH OBJECTIVE
- 2.2.2. ASSUMPTIONS

2.2.3.LIMITATIONS

3. RESEARCH METHODOLOGY

3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
- 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS

3.5. FORECASTING MODEL
3.6. MARKET SIZE ESTIMATION
- 3.6.1. BOTTOM-UP APPROACH
- 3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION

4. MARKET DYNAMICS

4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

5.1. VALUE CHAIN ANALYSIS
5.2. PORTER'S FIVE FORCES ANALYSIS
- 5.2.1. BARGAINING POWER OF SUPPLIERS
- 5.2.2. BARGAINING POWER OF BUYERS
- 5.2.3. THREAT OF NEW ENTRANTS
- 5.2.4. THREAT OF SUBSTITUTES
- 5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
- 5.3.1. MARKET IMPACT ANALYSIS
- 5.3.2. REGIONAL IMPACT
- 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

6.1. OVERVIEW
6.2. CONSUMABLES
6.3. EQUIPMENT
6.4. SOFTWARE SOLUTIONS

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

7.1. OVERVIEW
7.2. COMMERCIAL STAGE MANUFACTURING
7.3. RESEARCH STAGE MANUFACTURING

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. UPSTREAM PROCESSING
8.3. HARVESTING
8.4. DOWNSTREAM PROCESSING

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

9.1. OVERVIEW
9.2. LIFE SCIENCE COMPANIES
9.3. CONTRACT RESEARCH ORGANIZATIONS
9.4. CONTRACT MANUFACTURING ORGANIZATIONS
9.5. CELL BANKS

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

10.1. OVERVIEW
10.1. NORTH AMERICA
- 10.1.1. US
- 10.1.2. CANADA
10.2. EUROPE
- 10.2.1. GERMANY
- 10.2.2. FRANCE
- 10.2.3. UK
- 10.2.4. ITALY
- 10.2.5. SPAIN
- 10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
- 10.3.1. CHINA
- 10.3.2. INDIA
- 10.3.3. JAPAN
- 10.3.4. SOUTH KOREA
- 10.3.5. AUSTRALIA
- 10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
- 10.4.1. MIDDLE EAST
- 10.4.2. AFRICA
- 10.4.3. LATIN AMERICA

11. COMPETITIVE LANDSCAPE

11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
- 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
- 11.7.2. MERGER & ACQUISITIONS
- 11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
- 11.8.1. SALES & OPERATING INCOME,
- 11.8.2. MAJOR PLAYERS R&D EXPENDITURE.

12. COMPANY PROFILES

12.1. LONZA GROUP
- 12.1.1. COMPANY OVERVIEW
- 12.1.2. FINANCIAL OVERVIEW
- 12.1.3. PRODUCTS OFFERED
- 12.1.4. KEY DEVELOPMENTS
- 12.1.5. SWOT ANALYSIS
- 12.1.6. KEY STRATEGIES
12.2. THERMO FISHER SCIENTIFIC INC.
- 12.2.1. COMPANY OVERVIEW
- 12.2.2. FINANCIAL OVERVIEW
- 12.2.3. PRODUCTS OFFERED
- 12.2.4. KEY DEVELOPMENTS
- 12.2.5. SWOT ANALYSIS
- 12.2.6. KEY STRATEGIES
12.3. MERCK KGAA
- 12.3.1. COMPANY OVERVIEW
- 12.3.2. FINANCIAL OVERVIEW
- 12.3.3. PRODUCTS OFFERED
- 12.3.4. KEY DEVELOPMENTS
- 12.3.5. SWOT ANALYSIS
- 12.3.6. KEY STRATEGIES
12.4. WUXI APPTEC
- 12.4.1. COMPANY OVERVIEW
- 12.4.2. FINANCIAL OVERVIEW
- 12.4.3. PRODUCTS OFFERED
- 12.4.4. KEY DEVELOPMENTS
- 12.4.5. SWOT ANALYSIS
- 12.4.6. KEY STRATEGIES
12.5. CATALENT, INC.
- 12.5.1. COMPANY OVERVIEW
- 12.5.2. FINANCIAL OVERVIEW
- 12.5.3. PRODUCTS OFFERED
- 12.5.4. KEY DEVELOPMENTS
- 12.5.5. SWOT ANALYSIS
- 12.5.6. KEY STRATEGIES
12.6. SAMSUNG BIOLOGICS
- 12.6.1. COMPANY OVERVIEW
- 12.6.2. FINANCIAL OVERVIEW
- 12.6.3. PRODUCTS OFFERED
- 12.6.4. KEY DEVELOPMENTS
- 12.6.5. SWOT ANALYSIS
- 12.6.6. KEY STRATEGIES
12.7. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- 12.7.1. COMPANY OVERVIEW
- 12.7.2. FINANCIAL OVERVIEW
- 12.7.3. PRODUCTS OFFERED
- 12.7.4. KEY DEVELOPMENTS
- 12.7.5. SWOT ANALYSIS
- 12.7.6. KEY STRATEGIES
12.8. CHARLES RIVER LABORATORIES
- 12.8.1. COMPANY OVERVIEW
- 12.8.2. FINANCIAL OVERVIEW
- 12.8.3. PRODUCTS OFFERED
- 12.8.4. KEY DEVELOPMENTS
- 12.8.5. SWOT ANALYSIS
- 12.8.6. KEY STRATEGIES
12.9. CYTIVA
- 12.9.1. COMPANY OVERVIEW
- 12.9.2. FINANCIAL OVERVIEW
- 12.9.3. PRODUCTS OFFERED
- 12.9.4. KEY DEVELOPMENTS
- 12.9.5. SWOT ANALYSIS
- 12.9.6. KEY STRATEGIES
12.10. NOVASEP
- 12.10.1. COMPANY OVERVIEW
- 12.10.2. FINANCIAL OVERVIEW
- 12.10.3. PRODUCTS OFFERED
- 12.10.4. KEY DEVELOPMENTS
- 12.10.5. SWOT ANALYSIS
- 12.10.6. KEY STRATEGIES

13. APPENDIX

13.1. REFERENCES
13.2. RELATED REPORTS

細胞・遺伝子治療薬のバイオ製造の世界市場：製品タイプ・段階・用途・エンドユーザー・地域別の予測 (～2032年)

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type, By Usage, By Application, By End User And By Region - Forecast Till 2032

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界の細胞・遺伝子治療薬のバイオ製造市場：製品タイプ別

第7章世界の細胞・遺伝子治療薬のバイオ製造市場：段階別

第8章世界の細胞・遺伝子治療薬のバイオ製造市場：用途別

第9章世界の細胞・遺伝子治療薬のバイオ製造市場：エンドユーザー別

第10章世界の細胞・遺伝子治療薬のバイオ製造市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

3. RESEARCH METHODOLOGY

4. MARKET DYNAMICS

5. MARKET FACTOR ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

11. COMPETITIVE LANDSCAPE

12. COMPANY PROFILES

13. APPENDIX

細胞・遺伝子治療薬のバイオ製造の世界市場：製品タイプ・段階・用途・エンドユーザー・地域別の予測 (～2032年)

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type, By Usage, By Application, By End User And By Region - Forecast Till 2032

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

第5章 市場要因分析

第6章 世界の細胞・遺伝子治療薬のバイオ製造市場：製品タイプ別

第7章 世界の細胞・遺伝子治療薬のバイオ製造市場：段階別

第8章 世界の細胞・遺伝子治療薬のバイオ製造市場：用途別

第9章 世界の細胞・遺伝子治療薬のバイオ製造市場：エンドユーザー別

第10章 世界の細胞・遺伝子治療薬のバイオ製造市場：地域別

第11章 競合情勢

第12章 企業プロファイル

第13章 付録

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

3. RESEARCH METHODOLOGY

4. MARKET DYNAMICS

5. MARKET FACTOR ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

11. COMPETITIVE LANDSCAPE

12. COMPANY PROFILES

13. APPENDIX

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界の細胞・遺伝子治療薬のバイオ製造市場：製品タイプ別

第7章世界の細胞・遺伝子治療薬のバイオ製造市場：段階別

第8章世界の細胞・遺伝子治療薬のバイオ製造市場：用途別

第9章世界の細胞・遺伝子治療薬のバイオ製造市場：エンドユーザー別

第10章世界の細胞・遺伝子治療薬のバイオ製造市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章付録